fbpx
Aptose Biosciences (APTO)

Analysts Gives Aptose Biosciences (APTO) $9 Price Target

H.C. Wainwright analyst Joseph Pantginis raised his price target for Aptose Biosciences (APTO) to $9 from $6 and keeps a Buy rating on the shares.

Aptose’s shares have been starting to reflect the promise of CG-806, as the Street is realizing that CG-806 is not just a double FLT3/BTK inhibitor but also a mutationagnostic compound with the potential of gaining significant market share over approved drugs in several hematology-oncology malignancies, Pantginis tells investors in a research note.

According to TipRanks, Pantginis has a 45% success rate with an average return of 12.8%.

Pantiginis covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals, Aduro Biotech, and Onconova Therapeutics.

Currently, the analyst consensus on Aptose Biosciences is a Strong Buy with an average price target of $8.50, a 13.4% upside from current levels. In a report released this week, JonesTrading also maintained a Buy rating on the stock with a $12 price target.

Don't Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts and our next featured stock!
  • This field is for validation purposes and should be left unchanged.

Contributing Writers Wanted

Stockpence is currently seeking to expand our team of contributors. We’re looking for financial gurus & article writers to write about trending market news and investment ideas about the stock market.

If you’re interested please contact us!

Categories

Don't Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts and our next featured stock!
  • This field is for validation purposes and should be left unchanged.

Scroll to Top